Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 4:07 AM
Ignite Modification Date: 2025-12-25 @ 4:07 AM
NCT ID: NCT02384720
Eligibility Criteria: Inclusion Criteria: * Adults males/Females aged over 20years * Health screening examination within 60 days of the start (Interview, vital signs , 12-lead ECG, blood tests, urinalysis) . * The applicant who agreed in writing by told an explanation enough about the characteristics of the study drug, the purpose of the test and the details. Exclusion Criteria: * Subjects with clinically significant disease or history such as Liver, kidney, gastrointestinal, respiratory, musculoskeletal, endocrine, nervous psychiatric, blood tumor system and cardiovascular. (In particular, bronchial asthma, severe hepatic, renal failure, severe blood disorders, severe myasthenia gravis, cardiac dysfunction, peptic ulcer, etc.) * Who had acute disease or organ dysfunction within four weeks of the start of the test. * Who had significant hematologic disorders or donate whole blood within two months of the start of the test. * Significant neuropsychiatric or more. * Continued drug abuse. * Who has a history of drug and other hypersensitivity reactions. * Positive at Type B / C hepatitis , syphilis tests (VDRL), if in AIDS antibody test * Who took other clinical medicine within two months of the start of the test. * Who smokes or drinks within two weeks after dosing. * Who takes drugs regularly other than the mineral claim or vitamin. However, it depends on judgment of the researchers.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 20 Years
Study: NCT02384720
Study Brief:
Protocol Section: NCT02384720